NewsRoom Articles - Page 150 of 610

FridayDec 16, 2022 12:00 pm

Jupiter Wellness Inc. (NASDAQ: JUPW) Is ‘One to Watch’

Jupiter Wellness’s product pipeline addresses a range of underserved conditions, including hair loss, eczema, burns, and sexual wellness The company’s revenue is generated through OTC and consumer product sales, contract research agreements, and licensing royalties Jupiter Wellness recently announced that it has been approved to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs Jupiter Wellness (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary…

FridayDec 16, 2022 4:20 am

420 with CNW — FDA Seeks More Data in Fight Against Delta-8 THC Products

The FDA is seeking more data and evidence about the safety of cannabis derivatives while touting its progress to aid agencies at state level in exposing a company that sells Delta-8 THC chewables that have “damaging” after effects. The FDA has also been criticized recently due to lack of rules allowing hemp-derived products to be marketed as diet supplements. The agency insists on the need for more data and seeks support from the legislative arm of Congress. In a data collection bid, the FDA published a fact-finding notice seeking information on the availability and capabilities of able small-business sources to…

ThursdayDec 15, 2022 4:20 pm

420 with CNW — Choking Under Illicit Cannabis, Oregon Mulls Tougher Industry Laws

Almost a decade ago, voters in the state of Oregon approved a resolution that would legalize the recreational use of cannabis. This move made it the first state in the country to do so. Many believed that the drug’s legalization would reduce problems brought about by marijuana’s illegal manufacture in the state. This has not been the case, however, with the illicit production of the drug increasingly significantly since then. Legislators are now focused on making laws against the illicit growers even stricter, having heard numerous complaints from legal growers as well as law enforcement. Various regions in the state…

ThursdayDec 15, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study

Epilepsy affects one in every 26 people globally, with as many as one million ED visits, 280 hospital admissions, average hospital stays of 3.6 days, and an aggregate hospital cost of approximately $2.5 billion annually With its severity, prevalence, and overall cost implications, Lexaria is looking to offer an alternative option with its patented DehydraTECH(TM)-CBD Its recent animal seizure study, EPIL-A21-1, showed DehydraTECH-CBD to be equally or even more effective at lower doses than Epidiolex, one of the world’s leading anti-seizure medications and the world’s only commercially approved CBD-powered anti-seizure drug Lexaria looks to build on the findings so far…

ThursdayDec 15, 2022 4:20 am

420 with CNW — Cannabis Sales Slow as Pandemic Eases

Marijuana sales declined across the U.S. markets after the sale spike at the onset of the pandemic. This slowdown came after the industry faced economic and regulatory tests, causing people to channel their spending money elsewhere. Small enterprises find it hard to penetrate the populated market because there isn’t sufficient investment money. The cannabis industry is also on hold, awaiting regulation by the federal government to boost its sales nationwide. Oregon and Washington states, where the cannabis market is already established, are recording low sales at the retail outlets, a cannabis data firm Headset reports. In addition, sales were 11%…

WednesdayDec 14, 2022 4:20 pm

420 with CNW — Connecticut Governor Announces Cannabis Expungements to Start in 2023

Recently, Governor Ned Lamont of Connecticut announced that the state would start clearing low-level cannabis records in 2023. The governor revealed that the state had identified more than 40,000 eligible cases for possession that would automatically be processed at the start of next year, under a provision of the marijuana legalization measure he signed in 2021. Gov. Lamont explained that old low-level marijuana possession convictions shouldn’t hinder individuals from pursuing their professional, housing, career and educational aspirations. The governor also noted that this was especially important as employers in Connecticut sought to employ hundreds of thousands. Lamont’s office has also…

WednesdayDec 14, 2022 4:20 am

420 with CNW — DOJ Requests Additional Time in Cannabis Consumption Sites Case

The U.S. Justice Department is seeking for more time from a federal court to answer a lawsuit over the legality of drug-use sites where individuals use illegal substances in a clinically approved environment. The institution at the center of this case, the Overdose Prevention Center, had initially allowed a request for prior delays in the case, but they did not agree to the latest scenario. They filed for an opposition motion instead. This case has seen sustained delays in the past three years. The case was raised when the Department of Justice (under the Trump administration) denied a Philadelphia not-for-profit…

TuesdayDec 13, 2022 4:20 pm

420 with CNW — Virginia Task Force Calls for Stricter Rules on Unregulated THC Products

Earlier this year, the General Assembly of Virginia established a task force to study the increase in unregulated delta-8 THC products in the state; the assembly has recommended tougher rules for businesses that sell these products. Delta-8 THC is a psychoactive substance found in marijuana. Similar to delta-9 THC, which is found abundantly in marijuana, the compound produces a high when consumed, either through smoking or consuming an edible. The state of Virginia legalized the recreational use of cannabis for individuals aged 21 and above in July 2021. Under the enacted law, individuals can legally possess up to an ounce…

TuesdayDec 13, 2022 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements Lexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks) The company has also started investigating DehydraTECH-CBD as a…

TuesdayDec 13, 2022 4:20 am

420 with CNW — Federal Health Secretary Provides Update on Cannabis Scheduling Review

Secretary Xavier Becerra of the U.S. Department of Health and Human Services recently revealed during an event on overdose prevention that the agency was focused on completing a review on federal marijuana scheduling, as was recently directed by President Joseph Biden. President Biden ordered that a scheduling review be carried out by the department following his issuance of marijuana pardons, which saw thousands of individuals convicted of simple marijuana possession under federal law being released. The health secretary has thus far raised the issue with the head of the FDA, Dr. Robert M. Califf. The department head added that the…